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1078–5Objective. Supra-renal fixation in endovascular aneurysm repair (SR-EVR) is used to improve the proximal seal of aortic
stent grafts and appears to have minimal effect on serum creatinine. Serum cystatin C (CC) is a more sensitive marker of
renal injury and, unlike creatinine, is unaffected by non-renal influence. The aim of this study was to assess the true renal
effect of SR-EVR using this superior renal index.
Methods. Consecutive patients undergoing SR-EVR were prospectively recruited and compared to control groups under-
going open aneurysm repair (OR) and colorectal resection (CR). Serum CC and creatinine clearance (CrC) were deter-
mined pre-operatively and at 3, 6 and 12 months post-surgery. Renal function was compared using analyses of
covariance (ANCOVA).
Results. Sixty-five patients (M:F; 52:13, median age 74 years) were enrolled (24 SR-EVR, 28 OR, 13 CR). Pre-operative
renal function and risk factors were comparable (CC 1.04 mg/l, SR-EVR; 0.96 mg/l, OR; 0.97 mg/l, CR). Adjusting for
baseline renal function, there was no significant difference in CC or CrC between study and both control groups at 3, 6
or 12-months post-operatively.
Conclusion. Using cystatin C as a more sensitive renal index, there was no detectable evidence of kidney dysfunction at up
to one-year following EVR with uncovered bare-metal supra-renal fixation.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Contemporary opinion supports the use of uncovered
bare metal supra-renal (SR) fixation in devices for en-
dovascular repair (EVR) of abdominal aortic aneu-
rysm (AAA) for improved longer-term stent-graft
durability.1,2 Some authors have also suggested that
this practice may also serve to increase anatomical el-
igibility for EVR due to a reduction in the prohibitive
proximal neck morphology observed in many cases.3
Several uncontrolled studies have now been pub-
lished assessing the safety of bare metal supra-renal
fixation following SR-EVR. Although there is no cur-
rent evidence of any adverse renal effect, biochemical
renal assessment has relied almost exclusively on
blood urea nitrogen (BUN) and serum creatininesponding author. M. G. Wyatt, Northern Vascular Centre,
an Hospital, Freeman Road, High Heaton, NE7 7DN, United
om.
address: mike.wyatt@nuth.nhs.uk
884/000439+ 07 $34.00/0  2007 European Society for Vascula(sCr) methods.2,4e9 More recently, the low molecular
weight protein cystatin C (CC) has been validated as
a superior endogenous renal marker to sCr that may
enable the detection of sub-clinical renal injury.10,11
Using this more sensitive renal index (serum CC),
the aim of this study was to prospectively compare
renal function in SR-EVR patients with conventional
open AAA repairs (OR) and others undergoing lapa-
rotomy for non-vascular pathology.Patients and Methods
This was a prospective, controlled trial of patients un-
dergoing elective AAA repair at a major tertiary refer-
ral centre over a twelve-month period commencing
May 2002. Full ethical approval was obtained and all
patients were issued relevant information sheets with
appropriate consent documentation prior to inclusion.
During the study period, all AAA patients under-
going elective aortic repair were considered for studyr Surgery. Published by Elsevier Ltd. All rights reserved.
440 P. Davey et al.inclusion. Suitable patients with anatomically eligible
pathology were randomized as per EVAR-1 trial pro-
tocol12 to either EVR (study group) or OR (control
group). Consecutive primary endovascular repairs
and open AAA repairs performed outside EVAR-1
supplemented the EVR and OR limbs respectively.
In addition, another sequential but limited control
series of patients undergoing resection for colorectal
malignancy (CR) was also recruited. Pre-operative re-
nal failure with a requirement for renal replacement
therapy (i.e. haemo- or peritoneal dialysis) precluded
study inclusion.
At study enrollment, patient factors recorded in-
cluded sex, age, weight, smoking habit, maximal
antero-posterior AAA neck and sac sizes (calibrated
on CTscan) andmedical co-morbidity. The pre-operative
differential renal function in all patients undergoing
AAA repair (EVR & OR) was assessed by radio-
labelled DTPA (Diethylene Thiamine Penta-acetic
Acid) scanning. EVR-related procedural variables
recorded included device type, deployment success
and radiological contrast load.
All patients were reviewed at follow-up intervals of
3, 6 and 12 months. Biochemical markers of renal
function were recorded pre-operatively and at these
specific time points. Serum creatinine (sCr/mmoll1)
was analyzed on an Olympus 2700 multi-channel an-
alyser (Jaffe´ reaction-based) using the manufacturers
supplied reagents (Olympus Instruments, London),
providing a between-batch imprecision of less than
2% for each analyte. Creatinine clearance (CrC/
mlmin1) values were then derived using the vali-
dated Cockroft-Gault formula.13
A separate clotted blood sample was also taken for
serum CC measurement. After centrifugation for
10 minutes at 3000 rpm, serum was withdrawn and
storedat40 Cfor later analysis. SerumCCdetermina-
tion was by particle-enhanced turbidimetric immuno-
assay (PETIA) using the Cobas MIRA Plus automated
analyser. The DAKO Cystatin C PET Kit contains
polystyrene particles of uniform size, chemically cou-
pledwith rabbit antibody against humanCC.A reaction
between these immunoparticles and CC in a patient
specimen results in the formation of agglutinates and
a concomitant change in absorbance signal at 340 nm.
Interpolation on a calibration curve determines the CC
concentration of a specimen with a typical coefficient
of variance of less than 8%.
Radiological analysis of renal anatomy in AAA
patients was by contrast enhanced CT scan and intra-
operative angiography (EVR). Whereas all patients
underwent pre-operative CT scanning, only EVR pa-
tients and those OR subjects within the EVAR-1 trial
had 12-month follow-up images available forEur J Vasc Endovasc Surg Vol 35, April 2008comparison. Individual multi-slice (5 mm) analysis
was performed to assess both for the presence of
post-operative renal infarcts and evidence of overall
renal preservation (bipolar size).Data Analysis
All study information was anonymised and initially
stored within a Microsoft Excel (Microsoft Ltd.,
Reading, UK) spreadsheet. Relevant data was then ex-
ported to Minitab Version-13 for Windows (Minitab
Inc., PA, USA) software package for statistical and
graphical analysis. Unless indicated, median values
are quoted for continuous variables with the inter-
quartile range (IQR) in parentheses.
Methods of statistical analysis employed are de-
clared in the appropriate legends of Tables and Fig-
ures. Comparison of any observed change in renal
function (CrC and CC) at the specified follow-up in-
tervals was by analyses of covariance (ANCOVA).
Adjustment for baseline renal function was made for
all groups.Results
Sixty-five patients were recruited to the trial in the
12-month study period. Of these, 52 participants
required elective AAA repair (24 EVR and 28 OR)
whereas the remaining 13 underwent planned lapa-
rotomy for major colorectal resection (CR).
Twenty-two of the 52 AAA patients were random-
ized as part of the EVAR-1 trial (12 EVR & 10 OR).
The remaining 30 cases were therefore primary aortic
repairs (12 EVR and 18 OR). Primary EVR stents
were preferred forAAA repair in the setting of a hostile
abdomen. Regarding the 18 primary OR patients out-
side the EVAR-1 trial, 4 eligible patients refused
EVAR-randomization, 2 patients were <60-years old
and 12 cases were morphologically unsuitable (short
neck (n¼ 7); mural thrombus (n¼ 3) and excessive
angulation (n¼ 2)).Pre-Operative Status
Group-specific patient and aneurysm-related factors
are illustrated in Table 1. There was no significant
difference between the age range and sex distribution
between groups. Similarly, all study limbs were analo-
gous with respect to existing medical co-morbidity,
smoking habit and renal function. Although no patient
who required renal replacement therapypre-operatively
was enrolled for the study, thosewith renal impairment
Table 1. Pre-operative Patient & AAA-related factors
EVR (n¼ 24) OR (n¼ 28) CR (n¼ 13) p-value
Age (years) 74 (64e83) 75 (52e87) 72 (61e86) 0.86*
Sex (M:F) 21:3 23:5 8:5 0.59y
Co-Morbidity (%)
Ischaemic Heart Disease 12 (50) 11 (39) 5 (38) 0.44y
Hypertension 11 (46) 15 (54) 6 (46) 0.58y
Diabetes Mellitus 6 (25) 4 (14) 2 (15) 0.33y
Renal Impairment (no RRT) 4 (17) 5 (18) 2 (15) 0.31y
Tobacco Use 6 (25) 8 (29) 5 (38) 0.95y
Renal Function
Biochemical
sCr (Range)/mmoll1 110.5 (78e211) 110.5 (86e174) 100.5 (70e178) 0.99z
CrC (Range)/mlmin1 62 (38e89) 55 (25e92) 62 (22e82) 0.14z
Cystatin C (Range)/mgl1 1.04 (0.3e2.01) 0.96 (0.34e1.78) 0.97 (0.39e2.11) 0.55z
Radiological
Bipolar Renal Size (IQR)/mm 100 (20) 100 (14) - 0.61z
% Function Right Kidney 0.53 (0.02) 0.54 (0.03) - 0.82z
Aneurysmal Factors
Sac Size (Range)/mm 62 (55e85) 63.5 (44e103) - 0.14z
Neck Size (Range)/mm 22.5 (18e26) 21 (17e26) - 0.22z
Neck Length (Range)/mm 26.5 (14e48) 27 (16e30) - 0.48z
Inflammatory AAA 1 2 -
Symptomatic AAA 0 1 -
* ANOVA; y chi2; z 2 sample t-test.
441Impact of Supra-Renal EVR on Renal Function(defined as a ‘screening’ sCr value beyond the limits of
the normal reference range14) were not excluded.
For those patients presenting for AAA repair (EVR
and OR), maximal antero-posterior sac and neck sizes
were comparable (as per calibration for EVAR-1
trial12). There were three cases of inflammatory
AAA: one patient underwent ‘primary’ EVR follow-
ing failed OR and the other two were randomized to
the OR limb as part of EVAR-1. One aortic repair
was performed for a symptomatic (non-ruptured)
44 mm AAA in a 52-year old patient with a strong
family history of aneurysm rupture.
Peri-Operative Factors & Early Outcome
Two different types of supra-renally fixed endovascu-
lar stent were used in the study group. Thirteen pa-
tients received the Zenith device (Cook Inc.,
Bloomington, Ind.) with the other 11 cases undergoing
EVR using the Cordis system (Johnson & Johnson,
Miami, Florida). Median radiological contrast load
(300 mg Iodine/ml) during endovascular repair was
163 ml (range 110e350 ml).
Stent-graft implantation was technically successful
with satisfactory completion imaging in all but one
case (‘Patient 11’). Despite correct positioning prior
to deployment, the Zenith device encroached on the
left renal artery ostia with the covered segment of
stent after release. The right renal artery appeared un-
affected. Oliguria was noted as early as the theatre re-
covery room and this was unresponsive to aggressiveguided (CVP) fluid resuscitation, frusemide and man-
nitol. Poor renal function was confirmed on an early
post-operative DTPA scan, as the patient gradually
became anuric, fluid overloaded and acidotic. This re-
sulted in permanent haemo-dialysis dependence by
the third post-operative day.
No early renal complications were observed in
either of the control groups. Temporary supra-renal
aortic cross clamping was required in 2 open AAA
repairs in order to gain proximal control. In both of
these cases there were no associated adverse renal
sequelae.
The one early death of the entire series followed the
primary EVR of a 76 mmAAA in a patient with known
myelo-proliferative disorder andmassive splenomegaly.
Initially, his post-operative progress appeared satisfac-
tory andhewas actually discharged for further convales-
cence at day 6. Re-admitted two days later with sudden
back pain, an urgent CT scan demonstrated no stent-
relatedproblem.Withinaweek though,hehaddeveloped
severe chest sepsis and a consumptive coagulopathy
(DIC) that was ultimately responsible for his demise
from multi-organ failure.Late Outcome & Delayed Renal Function
Follow-up, Device Failure & Late mortality
Excluding late mortality, twelve-month follow-up
was complete in all but one OR patient (dropout
rate <0.5%). He withdrew for personal reasons atEur J Vasc Endovasc Surg Vol 35, April 2008
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Fig. 2. Adjusted time-specific change in Cystatin C (AN-
COVA method). Boxes represent the inter-quartile range
with a median bar. Whiskers define the 90% range.
442 P. Davey et al.10 weeks during a period of prolonged rehabilitation
following open aortic surgery.
Secondary re-intervention for device failure had
been required in only one EVR patient at 1-year fol-
low-up. In this case of initially uncomplicated Zenith
deployment, the pre-discharge CT scan revealed evi-
dence of a distal attachment site endoleak that was
managed successfully by endovascular limb exten-
sion. Unfortunately, the same patient required repair
of the access artery pseudo-aneurysm one month later
but has had no further problems since.
Only one of the five late deaths was due directly to
the presenting primary surgical pathology, whose late
follow-up is detailed below. Another EVR patient
died at 6-months from pancreatic cancer which was
not apparent on initial radiological studies. There
were two late deaths due to myocardial infarction
occurring at three (CR) and nine-months (OR) post-
operatively. Finally, one other CR patient expired at
6-months because of a cerebro-vascular accident.
Biochemical Renal Function
Change in renal function at specific time intervals
(3, 6 and 12-months) for each of the groups is shown
in the box-and-whisker plots of both Figs. 1 (CrC)
and 2 (CC). The annual median (IQR) change in CrC
from baseline was 2.1 (5.7) mlmin1 following EVR
compared to 3.1 (8.4) mlmin1 for OR and 4.6
(12.1) mlmin1 for CR. Similarly, at this follow-up
time there appeared to be no significant incremental
difference in CC between groups with a median CC
change from baseline of þ0.33 (0.22) mgl1 after
EVR and þ0.28 (0.54) mgl1, þ0.25 (0.74) mgl1 for
OR and CR respectively.
There was only one significant renal complication in
the study that concerned Patient 11 of the study limbC
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Eur J Vasc Endovasc Surg Vol 35, April 2008who developed significant dialysis-dependant renal
compromise after device deployment inadvertently
occluded the left renal artery during EVR. At 6-month
review this was reflected biochemically by a fall in CrC
to 13.4 mlmin1 (65 mlmin1 pre-op) and a concomi-
tant rise in CC to 5.96 mgl1 (1.62 mgl1 pre-op). Inter-
estingly, although the early DTPA scan confirmed
hypoperfusion, both kidneys did in fact enhance. A re-
nal duplex study (Day 8 post-EVR) confirmed this
bilateral kidney perfusion, albeit significantly reduced
on the left side (absent spectra). Also unexpected was
the presence of cortical enhancement of both kidneys
on a satisfactory routine post-EVR CT scan. Despite
discharge home this patient required multiple re-
admissions with problematic fluid status and cardiac
arrhythmias secondary to electrolyte imbalance, be-
fore dying at 8-months post-EVR with end-stage renal
failure. No other patient in EVR, OR or CR required
renal replacement therapy for any indication during
the entire study period.
Radiological Renal Analysis
The one-year follow-up CT images for both the EVR
and relevant OR cases were each compared to their
pre-operative scans. Follow-up imaging was not
performed in the 3 EVR patients who died within
1-year and considered incomplete (entire organ not
visualized) in four patients. Forty EVR and 20 OR
kidneys were therefore available for analysis.
Therewere twonew isolated renal infarcts identified
in the EVR group (8.3%) as opposed to none in those
who underwent open AAA repair. Neither case was
however accompanied with clinical or biochemical
evidence of renal dysfunction. At annual follow-up
bipolar renal size had not changed significantly from
pre-operative values in either group (paired t-test).
443Impact of Supra-Renal EVR on Renal FunctionMedian (IQR) EVR bipolar size was 100 (15) mm
(pre-op 100 (20) mm) and mean OR size 100 (18 mm
(pre-op 100 (14) mm).Discussion
Since the seminal paper of Malina et al.,5 several
groups have attempted to resolve the concerns of po-
tential renal effect following EVR with uncovered bare
metal supra-renal fixation.2,6e9,15 Unfortunately, these
early reports involved study groups of trans-renal
EVR patients without control subjects for comparison
and further evaluation of any fixation-specific renal
outcome was clearly required.
In 2002, Kra¨mer et al. published the first report of
fixation-specific renal outcome following EVR. In the
study, which was not concerned with biochemical re-
nal function, the post-operative CT images of 99 EVR
patients (both IR and SR) were reviewed at a minimal
follow-up of 12 months. Supra-renal fixation was
found not to be associated with an increased inci-
dence of renal infarcts post-EVR compared to endog-
rafts secured entirely with infra-renal fixation.16
Soon after, the Montefiore group reported compar-
ative renal outcome in 130 EVR (69 SR) patients with
a mean follow-up of 17 months.17 There was a signifi-
cant increase in sCr from pre-operative values in both
groups, yet no incremental difference between
fixation-type was observed. Similarly, CrC (Cockroft-
Gault) was significantly reduced for both SR and IR-
fixed EVR, but the extent of this fall was no different
between study limbs. Post-operative renal dysfunc-
tion (defined as sCr increase> 0.5 mg/dl above base-
line) developed in 10.7% (14/130) with again no
difference observed between groups.
Lau et al. also described an increase in sCr follow-
ing both IR and SR-EVR in their series of 89 patients.18
Although this was quoted to be statistically significant
at 1-year in the IR (and not the SR) group, the elevated
median sCr remained within the normal reference
range and group specific CrC values were unaffected.
The clinical implications of these findings are unclear.
These reports and a review of the literature indicate
a common reliance on the use of insensitive sCr
methods in order to assess biochemical renal function.
There are several inherent limitations with this ap-
proach. Firstly, sCr is formed by the non-enzymatic
conversion of muscle creatine and phosphocreatine
and hence its production rate is unstable, under direct
influence from many non-renal factors (e.g. dietary
preference, sex, muscle mass and surgical interven-
tion). The Cockroft-Gault formula attempts to correct
for these variables in the expression for creatinineclearance.13 Regardless, the glomerular filtration rate
(GFR) may still have to fall by at least 50% before
reflected in an elevated sCr (and reduced CrC).19e22
Finally, laboratory quantification of sCr is usually
based on the Jaffe´ reaction, a colorimetric assay with
complex-formation between creatinine and alkaline
picrate (‘Janovsky complex’). Unfortunately, other
chromogens are present in plasma leading to falsely
high levels of sCr e.g. uric acid, ketones, glucose
and plasma proteins.23 Serum cystatin C is generally
accepted as a better marker of excretory renal func-
tion.11,23e25 The low molecular weight protein is pro-
duced by all nucleated cells, is unaffected by sex or
muscle mass and is freely filtered and metabolised
in the kidney. It has been extensively validated by cor-
relation with the gold-standard measurements of GFR
(i.e. inulin clearance, iohexol and 51Cr-EDTA) and typ-
ically reported superior to sCr in this respect.24,26e30
Furthermore, CC appears more sensitive in signifying
earlier reductions in GFR (25e30%)10,11 and therefore
renal injury at a level that may be currently unde-
tected in those EVR patients with supra-renal stent
systems.
This study is not the first to employ CC as a sensi-
tive renal index post-EVR. Aho et al. compared the
short-term renal outcome of 15 EVR patients to OR
controls using CC, sCr and CrC as markers of renal
excretory function. This study found evidence of in-
creased glomerular filtration in both groups in the
early post-operative phase. Conversely, EVR did not
protect from proximal tubular damage in either group
(increased urinary N-acetyl-beta-D-glucosaminidase
(NAG) to creatinine ratio) despite no patient develop-
ing clinical evidence of renal impairment.31 Our study
assessed only the excretory (glomerular) component
of organ function since this is reported to offer the
best clinical estimate of functional renal mass, corre-
lating well with the severity of any observed renal
dysfunction.19,32,33 Over a longer 12-month follow-
up period using cystatin C, we have found no evi-
dence suggestive of significant renal impairment in
those patients undergoing SR-EVR, conventional
open AAA repair or laparotomy for colorectal resec-
tion.Admittedly, in view of the relatively small num-
ber of patients included in the study, its power is
must be taken in context. Furthermore, the unavoid-
able use of two specific differing endograft designs
within the study group may act as a source of bias.
Nevertheless, the findings should promote further
confidence in those advocating SR-EVR in the man-
agement of AAA.
Although there was no formalized renal protection
policy within our unit, all patients with renal impair-
ment (abnormally elevated sCr without a requirementEur J Vasc Endovasc Surg Vol 35, April 2008
444 P. Davey et al.for RRT) underwent careful intravenous fluid optimi-
zation with routine urinary catheterisation and central
venous monitoring where appropriate. If possible, the
administration of any contrast agent prior to EVR
(within 2 weeks) was avoided and the procedural vol-
ume used during EVR was restricted to the absolute
minimum required. Although it was not the policy
of the unit to routinely prescribe putative ‘reno-
protective’ agents such as dopexamine or mannitol,
a peri-operative intravenous infusion was commenced
if clinically indicated.
A specific intra-operative measure taken to mini-
mize renal injury was the angiographic imaging of
the renal arteries following partial stent deployment
(Fig. 3a). This was an attempt to confirm correct device
positioning (Fig. 3b) prior to complete release in order
to reduce the risk of renal artery compromise by the
covered segment of the stent. Unfortunately, the prac-
tice was not entirely failsafe and we describe in detail
the single case of the series with inadvertent deploy-
ment error (Patient 11). This case was particularly in-
teresting since the exact cause of renal failure was
essentially unknown. Initially, the encroachment of
the device on the left renal artery ostium at deploy-
ment was blamed for the acute renal failure (Fig. 3c).
Simple organ ischaemia alone cannot fully explain
the clinical deterioration since DTPA, renal duplex
and CT scanning revealed evidence of a maintained
(albeit impaired) bilateral renal perfusion. Perhaps
this reflected an initial patent renal collateral circula-
tion that was insufficient to maintain adequate renala b
Fig. 3. Patient 11: Intra-operative imaging. (a) Pre-deployment a
priately withdrawn: covered segment apparently below renal
with occlusion of left renal artery (splenic artery visible).
Eur J Vasc Endovasc Surg Vol 35, April 2008function. Cholesterol embolization could have also
played a role but this remained unproven as no renal
biopsy was performed and a post-mortem refused.
The incidence of renal infarcts in the study post-
EVR was comparable to the 8.3% reported by Kramer
et al.16 One case could plausibly be explained by the
intentional deployment of covered EVR stent over
a small accessory renal artery that was identified on
pre-operative imaging. The second instance most
likely occurred due to the embolism of debris present
in the region of the AAA neck during endograft
manipulation and deployment. In several other cases
there were transient procedural territorial renal
infarcts but all had completely resolved by 12-month
follow-up. Fortunately, both persistent cases were
clinically insignificant and not associated with any
biochemical renal derangement. Cayne et al. reported
a similar functional indifference to renal infarction
(using sCr and CrC methods) present in 5.8% of their
130 EVR cases.17
Renal failure following endovascular AAA repair is
generally considered multi-factorial in origin, occur-
ring in 6% of patients with normal pre-operative kid-
ney function.34 The longer-term CC data yielded by
this prospective work supports the hypothesis that
EVR devices with uncovered bare metal suprarenal
fixation have no detrimental effect per se on renal
function at up to 1-year post AAA repair. Indeed, con-
trary to the suspected negative impact of trans-renal
EVR these stents may actually in fact be protecting
patients from late renal failure courtesy of improved 
c
ngiogram: device positioned too cranially, (b) Device appro-
arteries, (c) Completion angiogram: device mal-deployment
445Impact of Supra-Renal EVR on Renal Functiondevice durability and hence a reduced requirement of
remedial secondary interventional procedures, each
with its own potential contrast-induced nephrotoxic
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